← All trials
NCT07075016
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 5, 2025
- Primary completion
- Dec 31, 2028
- Completion date
- Mar 31, 2029
- First posted
- Jul 20, 2025
- Last posted
- Aug 19, 2025
- Enrollment
- 227
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- HOVON - Dutch Haemato-Oncology AssociationLead sponsor
- Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y MielodisplasiasCollaborator
- Gruppo Italiano Malattie EMatologiche dell'AdultoCollaborator
- Swiss Group for Clinical Cancer ResearchCollaborator
- German-Austrian Acute Myeloid Leukemia Study GroupCollaborator
- United Kingdom AML Research NetworkCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.